A novel combination comprising the MEK inhibitor N-{3-[3- cyclopropyl- 5- (2- fluoro- 4- iodo- phenylamino)6,8- dimethyl- 2,4,7-trioxo- 3,4,6,7- tetrahydro- 2H- pyrido[4,3- d]pyrimidin- 1- yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a mTOR inhibitor, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or mTOR is beneficial, e.g. cancer.
